Bimzelx ®, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant …

Welcome to UCB in the United States. Healthcare Professionals; Patients; Investors; Facebook; Twitter; YouTube; LinkedIn; Instagram; Main navigation. UCB - Inspired by patients. Driven by …

Oct 18, 2023 · BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis Approval is …

Discover BIMZELX®, now approved to treat multiple indications including Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.

Sep 23, 2024 · Brussels (Belgium), September 23, 2024 – 07:00 (CEST) – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration …

ATLANTA, January 16, 2025 – 07:00 (EST) – UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each …

Bimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant …

BIMZELX ® (bimekizumab) is indicated for the treatment of: active PsA, alone or in combination with methotrexate, in adults who have had an inadequate response or who have been …

BIMZELX is indicated for the treatment of adults with active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, active ankylosing …

Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. The following data is for patients with Plaque Psoriasis.